Combining PARP Inhibition & Androgen Receptor-Signaling Inhibition Improves Survival in HRR-Deficient mCRPC
Talazoparib added to enzalutamide significantly improved survival and preserved QOL in men with mCRPC harboring homologous recombination repair gene alterations. For patients with...